Abstract. Although civilian physicians in the United States seldom encounter patients with leishmaniasis, therapeutic advances in endemic regions have opened the door to approaches that can be applied in this country. Advances revolve around the use of oral miltefosine in all forms of leishmaniasis and the use of short-course intravenous liposomal amphotericin B in visceral and possibly cutaneous infection. Lengthy, traditional intravenous treatment with pentavalent antimony (sodium stibogluconate) still has a role in the United States; however, although expensive, miltefosine and liposomal amphotericin B are considerably more appealing selections for initial therapy.
INTRODUCTION
Leishmaniasis, an intracellular protozoal infection in which tissue macrophages are targeted, is transmitted by sandfly bite and occurs in 98 countries. Fully expressed infection, caused by a diverse group of species, results in three basic clinical diseases-cutaneous (CL), mucosal (ML), or visceral (VL) leishmaniasis. Ten countries (Afghanistan, Iran, Iraq, Saudi Arabia, Algeria, Ethiopia, Sudan, Syria, Brazil, and Peru) contain 90% of cases of CL, six countries (India, Bangladesh, Nepal, Sudan, Ethiopia, and Brazil) house 90% of the world's VL burden, and ML is primarily but not exclusively a disease of South America. 1, 2 When civilian physicians in the United States are called on to manage patients with leishmaniasis, which is not often, it is usually in a predictable setting (Table 1) , most commonly travelers with localized CL. After the diagnosis has been secured, [2] [3] [4] [5] it is important to determine the extent of disease, region acquired, and infecting species (if possible), because this information may influence the choice of therapy, particularly in CL.
ML and VL, seldom encountered in the United States, are always treated. Although treatment is not required in CL in all instances, in practice, most patients in the United States receive some type of drug therapy. Irrespective of the treatment, patients with any form of leishmaniasis should be made aware of two possibilities: first, that the initial response may prove unsatisfactory, requiring retreatment, and second, that despite a satisfactory clinical response, relapse may still occur within the first 6-12 post-treatment months.
In endemic regions, multiple antileishmanial agents are in use or have been tested (Table 2 ). Although treatment efficacy may vary by species and/or region of acquisition, four drugs, known or likely active in all forms of leishmaniasis, are available to or can be obtained by US clinicians and used in both adults and children. Three are administered intravenously (IV; sodium stibogluconate, amphotericin B deoxycholate, and liposomal amphotericin B), and one is administered orally (miltefosine). 2 Other available drugs may be of limited, speciesspecific use, primarily in New World CL (NWCL)-oral ketoconazole for Leishmania (V.) panamensis or L. (Table 3) .
Although used for 60 years, the pentavalent antimonials remain active worldwide, with the exception of VL (kalaazar) acquired in northeastern India in the highly endemic Bihar State. 2 Elsewhere, antimony therapy (with retreatment, if necessary) produces cure rates in immunocompetent patients in the range of 70-90% in CL, 60-90% in ML, and 90% in VL. [2] [3] [4] [5] [6] Cure rates vary in a clinically frustrating way in CL and ML by endemic region, infecting species, disease severity, drug dose used, and particularly in VL, host immunocompetence. [1] [2] [3] [4] In 2012 in the United States, sodium stibogluconate is considered a satisfactory agent from the standpoint of efficacy. However, tangible drawbacks have always made antimony therapy unappealing. First, treatment is typically arduous. Frequent adverse clinical and/or biochemical reactions (Table 4) necessitate close monitoring and at least once weekly blood, urine, and electrocardiographic testing during therapy; treatment needs to be interrupted in up to~25% of patients but can be restarted and often completed. Second, sodium stibogluconate is not FDA-approved; thus, after CDC approval, local institutional review board (IRB) permission is also required. Third, daily IV outpatient administration for up to 20 days or longer may not be easy to accomplish, and an indwelling venous catheter may be needed. Fourth, although sodium stibogluconate is provided by a federal agency (CDC), home antibiotic infusion services may refuse to administer a drug that is not FDA-approved, and health insurance companies may decline its administration costs. Finally, the pentavalent antimonials cannot be used in pregnant women.
Given the preceding drawbacks, it is not surprising that civilian and military physicians are willing to consider reasonable (Table 3 ), is extremely active in VL and has been used as rescue therapy in both CL and ML. [2] [3] [4] Because the better-tolerated liposomal formulation is widely available in the United States, there is no reason to use the deoxycholate form to treat leishmaniasis. The only exception might be drug cost-not a minor issue if the patient is responsible for treatment expenses. Liposomal amphotericin B (AmBisome; Gilead Sciences, San Dimas, CA) is expensive; drug cost alone in the FDA-approved regimen for VL (total dose of 21 mg/kg) is $5,000-6,000 for a 70-kg person. Health insurance companies may well balk at this amount (as well as infusion and laboratory monitoring costs) in patients with CL, because this form of leishmaniasis is not an FDA-specified indication.
Liposomal amphotericin B is well-established in endemic regions for the treatment of VL; optimal short-course regimens regularly induce cure rates of 95%. 2, 19, 27 Indian VL is most responsive, whereas Brazilian and Sudanese VL seem less responsive. 2, 19 Although treatment experience is still quite limited, this agent is also likely active in CL and probably, ML. 9, 11, 29, 30, 32, 33 The FDA-approved regimen for liposomal amphotericin B in VL in immunocompetent patients is administered as a total dose of 21 mg/kg in an arbitrarily selected, cumbersome fashion-seven infusions over a lengthy 21-day period (Table 3) . 26 Drug is given over 2 hours, and treatment may be preceded by a 1-L saline infusion to reduce potential nephrotoxicity 29 and an oral antipyretic and/or antihistamine to manage infusion-associated fever and/or rigors ( Table 4) . As with any amphotericin B-containing product, some patients may not tolerate consecutive-day infusions. Although not often encountered with short-course therapy, the possibility of hypokalemia, anemia, or mild renal insufficiency requires one or perhaps, two times per week complete blood counts and monitoring of serum chemistries. 29 Liposomal amphotericin B, an FDA pregnancy category B drug, has been safely used to treat VL in pregnant women. 34 TREATMENT USING MILTEFOSINE Miltefosine (Impavido; Paladin Labs, St. Laurent, Quebec, Canada), the only effective oral agent in VL and ML, 2,28 is on the World Health Organization's Essential Medicines List and registered for VL and CL in 13 countries, but it is not FDAapproved. The drug can be obtained by US physicians from the manufacturer through an IND application to the FDA and local IRB approval (Table 2 ). Health insurance would not likely cover the cost of imported drug, which for 28 days of treatment at 150 mg/day, is approximately $3,000. Miltefosine is contraindicated in pregnant or breastfeeding women, and satisfactory contraception must be used in women of childbearing age during and for 3 months after treatment.
In endemic regions in immunocompetent patients, a 28-day regimen induces cure rates of 60-80% in ML 28 and usually 90% in VL. 2, 20 In NWCL, clinical cure responses range from ‡ L. guyanensis infection may respond poorly to pentavalent antimony but well to pentamidine; given the latter's toxicity, it is the only indication for this treatment. § Paromomycin is effective in VL 21 but is not FDA-approved or available for importation. Although inexpensive, paromomycin has no obvious appeal for US clinicians, because it requires one time daily intramuscular injection for 21 days.
¶ New formulation being tested. Cutaneous leishmaniasis (CL), particularly in travelers, is by far the form encountered in the United States; mucosal (ML) and visceral leishmaniasis (VL) are seen rarely.
* Most likely VL and most often reactivation of quiescent, previously acquired (subclinical or treated) infection provoked by acquired T-cell deficiency (e.g., advanced HIV disease) or iatrogenic immunosuppression by corticosteroid or antitransplant rejection therapy, cancer chemotherapy, or anticytokine treatment (e.g., antitumor necrosis factor therapy). [12] [13] [14] † Irrespective of the laboratory strain accidently injected, if infection develops, it is usually (but not invariably) confined to the skin. 15 CL is occasionally acquired in Texas and Oklahoma. 16 Blood-borne transmission of VL is theoretically possible in the United States.
TREATMENT OF LEISHMANIASIS IN THE UNITED STATES
50% to 91%, varying by infecting species and endemic region [35] [36] [37] [38] ; treatment in OWCL produces cures in 86-92%, but experience is quite limited. 39, 40 Miltefosine is available in 10-and 50-mg capsules, and it is given at approximately 2.5 mg/kg per day (up to 150 mg/day) ( Table 3 ). In practice, recommended dosing in adults with all forms of leishmaniasis translates to 150 mg/day for patients weighing 45 kg. Drug is taken in divided doses with meals to diminish nausea, vomiting, and/or diarrhea, common reactions during the first week of treatment (Table 4) . Serum chemistries should be monitored one time per week because of potential but fully reversible mild nephro-or less often, hepatotoxicity. ML is seldom encountered in the United States and has mimicked inflammatory or even neoplastic disease in periodic case reports. Although ML is a late clinical manifestation, early mucosal involvement in NWCL may not be infrequent, 41 and travelers returning from South America may simultaneously show cutaneous and mucosal lesions. 10, 11 Twenty-eight days of miltefosine therapy produce a satisfactory response in~80% of patients with mild ML and~60% in severe disease. 28 Thus, miltefosine represents a reasonable alternative to the conventional treatment approach (28 days of sodium stibogluconate), to which 60-90% of patients respond (Table 3) . 2, 4 (A Phase III trial of miltefosine versus pentavalent antimony [meglumine antimoniate] is underway in Brazil.) Responses are measured 6-12 months after therapy using specified clinical criteria and sufficient time to detect relapse. 4, 28 Liposomal amphotericin B, used at 20-35 mg/kg (total dose), may also be active, but reported experience in ML is very limited. The seven-infusion, 21-day FDA-approved regimen for liposomal amphotericin B in immunocompetent patients with VL (Table 3) is inefficient, because total dose administered seems to be the key efficacy factor and not the number of infusions or duration of treatment. 2, 19, 27 Indeed, the particular pharmacokinetics and macrophage-targeted distribution of the liposomal formulation, along with good tolerability, opened the door to short-course therapy in VL and the use of up to 10 mg/kg per infusion. 2, 19, 27 For US patients with VL acquired in the Indian subcontinent, delivering 10 mg/kg liposomal amphotericin B as a single dose 27 or 15 mg/kg through 5 consecutive day infusions of 3 mg/kg 2 should be effective (Table 3) . For VL originally acquired in Table 3 Representative treatment regimens for immunocompetent patients in the United States. Infusion-associated fever/chills (3-49%), nausea/vomiting or diarrhea (4-10%), rash (2-15%), back pain (2-10%), or increased creatinine (1-45%) Miltefosine Nausea/vomiting (6-76%), diarrhea (3-24%), headache (23-27%), motion sickness (29%), increased creatinine (1-32%), or LFTs other regions, the therapeutic target should be a total dose of 18-20 mg/kg. In VL acquired in the Mediterranean region, two infusions of 10 mg/kg on consecutive days have been used successfully in children. 42 If liposomal amphotericin B could not be used, obtaining miltefosine would, on balance, provide a preferable alternative to sodium stibogluconate, unless immediate treatment was required or the patient was pregnant. High-level resistance precludes the use of sodium stibogluconate in VL acquired in Bihar State, India, where~45% of the world's cases of kala-azar are found. 2 Unless disease is well-advanced, most immunocompetent patients with VL respond well to therapy. Symptomatic improvement with resolution of fever usually occurs within the first week; within 2-4 weeks, spleen size is smaller, and pancytopenia improves. 2 A complete response (definitive cure) designation, however, is not assigned until six additional clinically unremarkable months have passed, the period in which most post-treatment failures (relapses) occur. 2, 27 TREATMENT OF CUTANEOUS INFECTION Hastening resolution of active infection, reducing scarring, and decreasing the chance of recurrence are the goals of treatment in both NWCL and OWCL. For NWCL acquired in South America (where~90% of cases are caused by L. braziliensis), 1 attempting to prevent mucosal disease is an additional objective. Tables 3, 5 , and 6 summarize treatment approaches and generally accepted indications for initiating therapy in CL.
Although 70-88% of localized infections caused by L. mexicana (NWCL) or L. major (OWCL) heal spontaneously within 3-4 months, 2, 22, 44 treatment is given if an indication listed in Table 6 is present. In addition, although close observation alone is reasonable in selected cases, patients are often understandably uneasy with no immediate therapy. Thus, in practice in the United States, treatment of infections caused by L. mexicana or L. major is typically requested and given.
With the exception of NWCL caused by L. guyanensis, which may be less responsive, 2,3 daily treatment with sodium stibogluconate for 10-20 (OWCL) or 20 days (NWCL) is considered conventional. If infection caused by L. major or L. mexicana (which virtually never leads to ML) is treated, 10 rather than 20 days of therapy seems satisfactory. 2, 3, 43 Direct treatments (e.g., intralesional injections of sodium stibogluconate or formulations of topical paromomycin) [1] [2] [3] are used regularly in endemic regions as well as Europe and the United Kingdom. These and other direct treatments, including FDA-approved thermotherapy, 3 have been reported on or are being tested in this country. 22, 43 However, few US civilian physicians are experienced in direct lesion treatments, and none would be appropriate in patients at risk for ML.
Ideally, clear-cut results from well-executed clinical trials would guide US clinicians to alternatives to sodium stibogluconate in CL. However, such information has been hard to find. 23, 24 Nevertheless, recent cumulative experience with miltefosine now seems sufficient enough to recommend its use as alternative initial therapy in NWCL 20, [35] [36] [37] [38] and probably OWCL. 39, 40 Because cure rates vary in NWCL and experience is limited in OWCL, miltefosine-treated patients need to know that retreatment with another, less convenient agent may be necessary.
Although experience in CL with liposomal amphotericin B is also limited, 9, 29, 32, 33 using the FDA-approved total dose for VL (21 mg/kg) in a more efficient regimen (e.g., seven consecutive one time per day infusions of 3 mg/kg) has similar appeal as an alternative to sodium stibogluconate. 32 Oral ketoconazole may also be an alternative initial therapy in NWCL caused by L. panamensis or L. mexicana. 45 If the infecting Leishmania strain in a patient with CL has not been identified, none of the preceding species-specific approaches or treatments (Tables 3 and 5 ) would be options. Reasonable assumptions about the responsible species can, however, sometimes be made by knowing where infection was likely acquired. Nevertheless, in the absence of species identification, a full course of treatment using sodium stibogluconate, miltefosine or perhaps, liposomal amphotericin B should be given (Table 3) .
With any treatment, physical manifestations in CL take time to improve, and progress may seem slow. Criteria for judging clinical improvement and successful therapy vary. However, by 4-6 weeks after effective drug treatment, most ulcers heal (reepithelialize); if not, lesion size should be diminished by at least two-thirds accompanied by clear-cut improvement in local inflammation. 2 If by 6-8 weeks after treatment, lesion size and number have not diminished appreciably, any additional observation should be brief while making preparations for different therapy. The overall response (e.g., extent of ulcer reepithelialization) is usually not formally measured until 12 weeks post-treatment, at which time decisions about continued observation versus retreatment can also be made. Because treated CL may relapse, complete responses are not assigned until 6 or preferably, 12 months after apparently successful therapy.
TREATMENT IN IMMUNOCOMPROMISED PATIENTS
A T cell (primarily CD4 cell)-dependent, Th1-type cytokinedriven inflammatory response is required in leishmaniasis for macrophage activation, inhibition of intracellular replication, and parasite killing. 2 This mechanism seems to impart multiple host defense effects: (1) spontaneous control of many infections, (2) amplification and enhanced durability of initial treatment responses, and (3) prevention of remote reactivation of spontaneously controlled or treated infection by maintaining residual intracellular parasites in a clinically quiescent state. 2, 46 Deficient T-cell mechanisms, especially resulting from reduced CD4 cell number, derail the preceding effects, undermining initial responsiveness to chemotherapy, durability of an apparent therapeutic response, and prevention of recrudescence. Best documented in VL and less often in CL and ML, two predictable settings compromise antileishmanial defense-advanced human immunodeficiency virus (HIV) disease and T-cell dysfunction induced by iatrogenic immunosuppression (Table 1) . 2, [12] [13] [14] 46 Although treatment failures and/or relapses in CL or ML associated with HIV coinfection or deficient T-cell function may occur, 12 it is not clear that standard therapeutic approaches should necessarily be modified. In contrast, responses in CD4 cell-depleted (e.g., 200 CD4 cells/mm 3 ) HIV-coinfected patients with VL are different. These patients, mostly with reactivated infection, often have difficulty in tolerating antileishmanial agents, especially pentavalent antimony, 47 and with the possible exception of those patients given liposomal amphotericin B, 12,26,47,48~3 0-45% respond poorly to or entirely fail initial treatment. 12 In addition, in coinfected patients who do show clinical improvement, the post-treatment parasitologic effect is also often suboptimal. Thus, except for recent data from India (which paint an extraordinarily different, more optimistic picture), 48 initial clinical responses are not usually durable, and relapses are common unless remission can be maintained by optimizing highly-active antiretroviral therapy (HAART) in conjunction with suppressive antileishmanial therapy. However, regimens to prevent subsequent or repeated relapses are not well-standardized, and they do not necessarily meet with success over the long term. 12 If the HAART-induced CD4 cell count remains at 200 cells/mm 3 for 6 months, it may be possible to discontinue antirelapse (maintenance) treatment. 12 In HIV-associated VL, the notion that initially giving more drug and/or lengthening treatment duration will produce better early or long-term results has little firm basis. Nevertheless, the FDA-approved regimen for liposomal amphotericin B in this setting involves 10 infusions of 4 mg/kg (total dose of 40 mg/kg) given over 38 days. 26 It would seem just as reasonable to administer a conventional course of liposomal amphotericin B (Table 3 ) and in patients who show clinical improvement, begin a maintenance regimen (e.g., 5 mg/kg every 2-3 weeks). 12 How to best attempt to induce remission in an entirely unresponsive patient or one who experiences multiple relapses is unclear; logic suggests considering using both liposomal amphotericin B and miltefosine in such situations. 47 VL patients with preserved CD4 cell number but impaired T-cell function resulting from iatrogenic immunosuppression respond differently. Such patients include those patients in whom reactivation of prior subclinical infection was provoked by treatment with corticosteroids, cancer chemotherapy, an anticytokine agent, or most frequently, antitransplant rejection drugs. 2, 13, 14 Although some of these patients do not respond to initial therapy and/or experience early post-treatment relapse, overall, they respond surprisingly well and durably to conventional treatment regimens. 13 In addition and for unclear reasons, long-term suppressive antileishmanial therapy seldom seems necessary in treated transplant recipients who are maintained on immunosuppressive agents. 13 Experience with CL and ML in iatrogenically immunosuppressed individuals is too limited to judge if similar conclusions also apply to their responses to conventional treatment approaches.
